glp 1 triple agonist A peptide of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss A review of an investigational

Xanthopoulos A, Starling RC, Kitai T, Triposkiadis F

The apparent contradiction between these potential protective mechanisms and clinical observations of retinopathy worsening likely reflects the complex interplay between rapid metabolic changes and pre-existing vascular damage

Clinical pharmacology biopharmaceutics review: Mounjaro

Sarcopenic obesity in older adults: a clinical overview

[DOI] [PubMed] [Google Scholar] 39.Vanhoutte P.M., Shimokawa H., Feletou M., Tang E.H.C

The concept of incretin effect was first proposed by Creutzfeldt in the 1970s ( 2 Physiology of incretins 2.1 Discoveries of GIP and GLP-1 The first incretin, GIP, was purified from canine intestinal extracts in the late 1960s ( + secretion ( Figure 1 Section A]